{"organizations": [], "uuid": "e426ae13018ef9cc34566392d0990c5685794806", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-macrogenics-enters-research-collab/brief-macrogenics-enters-research-collaboration-with-roche-idUSFWN1OZ0MP", "country": "US", "domain_rank": 408, "title": "BRIEF-Macrogenics Enters Research Collaboration With Roche", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-01-04T20:34:00.000+02:00", "replies_count": 0, "uuid": "e426ae13018ef9cc34566392d0990c5685794806"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-macrogenics-enters-research-collab/brief-macrogenics-enters-research-collaboration-with-roche-idUSFWN1OZ0MP", "ord_in_thread": 0, "title": "BRIEF-Macrogenics Enters Research Collaboration With Roche", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "negative"}, {"name": "hoffmann-la roche", "sentiment": "none"}, {"name": "f. hoffmann-la roche", "sentiment": "none"}, {"name": "macrogenics", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "macrogenics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 4 (Reuters) - Macrogenics Inc:\n* MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE\n* MACROGENICS INC - UNDER TERMS OF AGREEMENT, ROCHE WILL PAY MACROGENICS AN UPFRONT PAYMENT OF $10 MILLION\n* MACROGENICS INC - MACROGENICS WILL ALSO BE ELIGIBLE TO RECEIVE UP TO $370 MILLION IN POTENTIAL MILESTONE PAYMENTS AND ROYALTIES ON FUTURE SALES\n* MACROGENICS INC - FURTHER DETAILS ABOUT TRANSACTION ARE NOT DISCLOSED\n* MACROGENICS INC - ENTERED INTO A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC. Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-04T20:34:00.000+02:00", "crawled": "2018-01-04T21:15:25.010+02:00", "highlightTitle": ""}